LAUREL

Phase I/open-label trial, dose escalation study of INKmune therapy

LAUREL is a Phase I/open-label trial, dose escalation study of INKmune therapy in patients with: - MDS-EB-1/2, MDS-CMML 1-2 who have completed treatment with Azacytidine (AZA), and not achieved complete remission (CR) who are not thought to be fit for intensive chemotherapy.

Patients with AML in complete remission (or complete remission with incomplete count recovery) unsuitable for intensive chemotherapy or allogeneic stem cell transplantation.

Patients with relapsed MDS or AML post-allogeneic stem cell transplant, with slowly progressive disease unsuitable for intensive chemotherapy.

The study is being conducted in the UK and Greece.